Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones, Rachel B ; Furuta, Shunsuke ; Cohen Tervaert, Jan Willem ; Hauser, Thomas ; Luqmani, Raashid ; Morgan, Matthew D ; Peh, Chen Au ; Savage, Caroline O ; Segelmark, Mårten LU
and Tesar, Vladimir
, et al.
(2015)
In Annals of the Rheumatic Diseases
74(6).
p.1178-1182
- Abstract
- The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5265279
- author
- Jones, Rachel B
; Furuta, Shunsuke
; Cohen Tervaert, Jan Willem
; Hauser, Thomas
; Luqmani, Raashid
; Morgan, Matthew D
; Peh, Chen Au
; Savage, Caroline O
; Segelmark, Mårten
LU
and Tesar, Vladimir
, et al. (More)
- Jones, Rachel B
; Furuta, Shunsuke
; Cohen Tervaert, Jan Willem
; Hauser, Thomas
; Luqmani, Raashid
; Morgan, Matthew D
; Peh, Chen Au
; Savage, Caroline O
; Segelmark, Mårten
LU
; Tesar, Vladimir
; van Paassen, Pieter
; Walsh, Michael
; Westman, Kerstin
LU
and Jayne, David Rw
(Less)
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 74
- issue
- 6
- pages
- 1178 - 1182
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:25739829
- wos:000354371200034
- scopus:84935002700
- pmid:25739829
- ISSN
- 1468-2060
- DOI
- 10.1136/annrheumdis-2014-206404
- language
- English
- LU publication?
- yes
- id
- 9e097ce3-c38b-4eaf-934f-05394a1e12df (old id 5265279)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25739829?dopt=Abstract
- date added to LUP
- 2016-04-01 10:53:23
- date last changed
- 2024-11-05 18:24:25
@article{9e097ce3-c38b-4eaf-934f-05394a1e12df,
abstract = {{The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.}},
author = {{Jones, Rachel B and Furuta, Shunsuke and Cohen Tervaert, Jan Willem and Hauser, Thomas and Luqmani, Raashid and Morgan, Matthew D and Peh, Chen Au and Savage, Caroline O and Segelmark, Mårten and Tesar, Vladimir and van Paassen, Pieter and Walsh, Michael and Westman, Kerstin and Jayne, David Rw}},
issn = {{1468-2060}},
language = {{eng}},
number = {{6}},
pages = {{1178--1182}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.}},
url = {{http://dx.doi.org/10.1136/annrheumdis-2014-206404}},
doi = {{10.1136/annrheumdis-2014-206404}},
volume = {{74}},
year = {{2015}},
}